Mortality-Related Risk Factors for Coronavirus Disease (COVID-19)-Associated Mucormycosis: a systematic review and meta-analysis.

IF 2.3 Q3 INFECTIOUS DISEASES

Current Fungal Infection Reports Pub Date : 2022-01-01 Epub Date: 2022-08-11 DOI:10.1007/s12281-022-00440-2

Vahid Reza Ostovan, Reza Tabrizi, Hanieh Bazrafshan, Zahra Bahrami, Hajar Khazraei, Samaneh Khazraei, Afshin Borhani-Haghighi, Mohsen Moghadami, Matthew Grant

{"title":"Mortality-Related Risk Factors for Coronavirus Disease (COVID-19)-Associated Mucormycosis: a systematic review and meta-analysis.","authors":"Vahid Reza Ostovan, Reza Tabrizi, Hanieh Bazrafshan, Zahra Bahrami, Hajar Khazraei, Samaneh Khazraei, Afshin Borhani-Haghighi, Mohsen Moghadami, Matthew Grant","doi":"10.1007/s12281-022-00440-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) can increase the susceptibility of individuals to contracting mucormycosis through several mechanisms. Nowadays, coronavirus disease (COVID-19)-associated mucormycosis (CAM) is a serious public health concern, particularly in developing countries. This meta-analysis aims to identify the risk factors that affect the mortality rate of patients with CAM.Recent findings: We systematically searched PubMed, Google Scholar, Scopus, Cochrane library, and preprint databases using pertinent keywords and the reference lists of the included relevant articles from inception till October 27, 2021. In order to reduce the effects of small-scale studies, we only selected cross-sectional, case-control, and cohort studies and case series with at least four patients. We identified 26 articles that included 821 patients with CAM. The effect size (ES) of mortality rate was 28% (95% confidence interval (CI) 20%-38%; I2 =82.28%; p for Cochran Q<0.001). The CAM patients with a history of comorbidities other than diabetes (malignancies, transplant, or renal failure), mechanical ventilation due to COVID-19, pulmonary and cerebral mucormycosis, and those who only received medical treatment for mucormycosis had the highest mortality rate.Summary: Coronavirus disease (COVID-19)-associated mucormycosis (CAM) is a major public health problem, particularly in developing countries. Severe COVID-19 infection, history of mechanical ventilation, early CAM, comorbidities other than diabetes (malignancies, transplant, or renal failure), pulmonary and rhino-orbito-cerebral mucormycosis, and delivering only medical treatment for mucormycosis were the worst prognostic factors in CAM patients. Identifying the mortality-related risk factors in CAM patients may help reduce the mortality rate by implementing optimized treatment approaches.Supplementary information: The online version contains supplementary material available at 10.1007/s12281-022-00440-2.","PeriodicalId":10813,"journal":{"name":"Current Fungal Infection Reports","volume":" ","pages":"143-153"},"PeriodicalIF":2.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366801/pdf/","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Fungal Infection Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12281-022-00440-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 4

Abstract

Purpose of review: Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) can increase the susceptibility of individuals to contracting mucormycosis through several mechanisms. Nowadays, coronavirus disease (COVID-19)-associated mucormycosis (CAM) is a serious public health concern, particularly in developing countries. This meta-analysis aims to identify the risk factors that affect the mortality rate of patients with CAM.

Recent findings: We systematically searched PubMed, Google Scholar, Scopus, Cochrane library, and preprint databases using pertinent keywords and the reference lists of the included relevant articles from inception till October 27, 2021. In order to reduce the effects of small-scale studies, we only selected cross-sectional, case-control, and cohort studies and case series with at least four patients. We identified 26 articles that included 821 patients with CAM. The effect size (ES) of mortality rate was 28% (95% confidence interval (CI) 20%-38%; I² =82.28%; p for Cochran Q<0.001). The CAM patients with a history of comorbidities other than diabetes (malignancies, transplant, or renal failure), mechanical ventilation due to COVID-19, pulmonary and cerebral mucormycosis, and those who only received medical treatment for mucormycosis had the highest mortality rate.

Summary: Coronavirus disease (COVID-19)-associated mucormycosis (CAM) is a major public health problem, particularly in developing countries. Severe COVID-19 infection, history of mechanical ventilation, early CAM, comorbidities other than diabetes (malignancies, transplant, or renal failure), pulmonary and rhino-orbito-cerebral mucormycosis, and delivering only medical treatment for mucormycosis were the worst prognostic factors in CAM patients. Identifying the mortality-related risk factors in CAM patients may help reduce the mortality rate by implementing optimized treatment approaches.

Supplementary information: The online version contains supplementary material available at 10.1007/s12281-022-00440-2.

Abstract Image

查看原文本刊更多论文

冠状病毒病(COVID-19)相关毛霉菌病的死亡相关危险因素:系统综述和荟萃分析

综述目的:严重急性呼吸综合征-冠状病毒-2 (SARS-CoV-2)可通过多种机制增加个体感染毛霉菌病的易感性。如今，冠状病毒病(COVID-19)相关毛霉菌病(CAM)是一个严重的公共卫生问题，特别是在发展中国家。本荟萃分析旨在确定影响CAM患者死亡率的危险因素。近期发现:我们系统地检索了PubMed、Google Scholar、Scopus、Cochrane library和预印本数据库，使用相关关键词和纳入的相关文章的参考文献列表，检索时间从建库到2021年10月27日。为了减少小规模研究的影响，我们只选择了至少有4名患者的横断面、病例对照和队列研究和病例系列。我们确定了26篇文章，其中包括821例CAM患者。死亡率的效应量(ES)为28%(95%置信区间(CI) 20% ~ 38%;I2 = 82.28%;总结:冠状病毒病(COVID-19)相关毛霉菌病(CAM)是一个重大的公共卫生问题，特别是在发展中国家。严重的COVID-19感染、机械通气史、早期CAM、糖尿病以外的合并症(恶性肿瘤、移植或肾功能衰竭)、肺部和鼻-眶-脑毛霉菌病以及仅对毛霉菌病进行药物治疗是CAM患者预后最差的因素。识别CAM患者的死亡相关危险因素有助于通过实施优化的治疗方法来降低死亡率。补充信息:在线版本包含补充资料，提供地址为10.1007/s12281-022-00440-2。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Fungal Infection Reports INFECTIOUS DISEASES-

CiteScore

3.10

自引率

7.10%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of fungal infections. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as advances in diagnosis, current and emerging management approaches, and genomics and pathogenesis. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. Commentaries from well-known figures in the field are also provided, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.